Somatostatin Analog Therapy in Small Cell Lung Cancer

Alfredo Tartarone, Rosa Lerose, Michele Aieta

Research output: Contribution to journalArticle


Chemotherapy represents the cornerstone of treatment for patients with small cell lung cancer (SCLC); however, standard therapy has reached a plateau in improving patient survival with overall disappointing results. The demonstration that SCLC expresses neuroendocrine markers, such as somatostatin (SST) receptors, has led to use SST analogs or radiolabeled SST analogs in the treatment of SCLC patients. In the current review, we would focus on the possible role of SST analogs in SCLC.

Original languageEnglish
Pages (from-to)239-242
Number of pages4
JournalSeminars in Nuclear Medicine
Issue number3
Publication statusPublished - May 1 2016

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Somatostatin Analog Therapy in Small Cell Lung Cancer'. Together they form a unique fingerprint.

  • Cite this